GLP-1R agonist withdrawal effect on weight loss and cardiovascular risks remains unmet need:… Zepbound is Eli Lilly’s new glucagon-like peptide-1/gastric inhibitory polypeptide (GLP-1/GIP) dual agonist, approved by the FDA…
